These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16648936)

  • 1. Persistent painful indurated erythema secondary to bosentan.
    Gallardo F; Gil A; Comín J; Molina L; Iglesias M; Pujol RM
    Acta Derm Venereol; 2006; 86(2):186-7. PubMed ID: 16648936
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bosentan: a new pillar in the treatment of pulmonary hypertension?].
    Matthes J; Groner F
    Dtsch Med Wochenschr; 2006 May; 131(18):1031-4. PubMed ID: 16673229
    [No Abstract]   [Full Text] [Related]  

  • 3. Bosentan enters market with risk management program.
    Thompson CA
    Am J Health Syst Pharm; 2002 Mar; 59(6):506. PubMed ID: 11908242
    [No Abstract]   [Full Text] [Related]  

  • 4. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
    Dhillon S; Keating GM
    Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does rapid dose titration affect the hepatic safety profile of Bosentan?
    Suntharalingam J; Hodgkins D; Cafferty FH; Hughes RJ; Pepke-Zaba J
    Vascul Pharmacol; 2006 Jun; 44(6):508-12. PubMed ID: 16713365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
    Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
    Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan in pulmonary hypertension secondary to unilateral absence of a pulmonary artery.
    Ling Y; Mei F; Wang Y; Feng Y
    Int J Cardiol; 2015 Jul; 191():34-5. PubMed ID: 25965593
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bosentan in pulmonary hypertension].
    Heinzl S
    Med Monatsschr Pharm; 2002 Mar; 25(3):74-6. PubMed ID: 11925765
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G; von Hunnius P
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed hypersensitivity to bosentan.
    Romano A; Giovannetti A; Caruso C; Rosato E; Pierdominici M; Salsano F
    Allergy; 2009 Mar; 64(3):499-501. PubMed ID: 19220223
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe necrotising leucocytoclastic vasculitis in a patient taking bosentan.
    Gasser S; Kuhn M; Speich R
    BMJ; 2004 Aug; 329(7463):430. PubMed ID: 15321900
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bosentan].
    Taéron C
    Rev Infirm; 2005 Feb; (108):33-4. PubMed ID: 15816717
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
    Mohamed WA; Ismail M
    J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 18. Hidden hazards of Bosentan therapy in pulmonary hypertension.
    Sethi S; Sethi R; Wareham C
    Ann Card Anaesth; 2008; 11(2):138; author reply 138-9. PubMed ID: 18603762
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan for pulmonary hypertension.
    Dietrich CG; Geier A; Lammert F
    N Engl J Med; 2002 Jul; 347(4):292-4; author reply 292-4. PubMed ID: 12141332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.